Opendata, web and dolomites

TACT SIGNED

Targeted Anti-Cancer Therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "TACT" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITE DE STRASBOURG 

Organization address
address: RUE BLAISE PASCAL 4
city: STRASBOURG
postcode: 67081
website: http://www.unistra.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙089˙569 €
 EC max contribution 3˙089˙569 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2019
 Funding Scheme MSCA-ITN-ETN
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2024-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE DE STRASBOURG FR (STRASBOURG) coordinator 549˙604.00
2    THE QUEEN'S UNIVERSITY OF BELFAST UK (BELFAST) participant 606˙345.00
3    ALMAC DISCOVERY LTD UK (CRAIGAVON) participant 303˙172.00
4    UNIVERSITY COLLEGE LONDON UK (LONDON) participant 303˙172.00
5    SPIROCHEM AG CH (BASEL) participant 281˙276.00
6    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) participant 274˙802.00
7    WAGENINGEN UNIVERSITY NL (WAGENINGEN) participant 265˙619.00
8    HEIDELBERG PHARMA RESEARCH GMBH DE (LADENBURG) participant 252˙788.00
9    TECHNISCHE UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 252˙788.00

Map

 Project objective

Antibody-Drug Conjugates (ADCs) are fast growing classes of oncology therapeutics. They consist in a highly potent cytotoxic drug connected via a linker to an antibody that is specifically targeting certain tumor markers. By combining the cytotoxicity of the drug and the targeting properties of the antibody, ADCs kill cancer cells whilst leaving the healthy cells unaffected, a marked improvement compared to classical chemotherapies. However, limitations still exist which could fuel the development of new generations of ADCs with improved therapeutical properties. Targeted Anti-Cancer Therapies (TACT) is an innovative, international, multidisciplinary training and research programme which thus aims to train 11 Early- Stage Researchers (ESRs) on the development of state-of-the-art anti-cancer therapeutics and equip them with transferable, future career-enhancing skills to create the next generation of experts in Europe. More specifically, TACT’s research programme will focus on key priorities for the conception of new and more potent generations of Protein-Drug Conjugates (PDCs): site-specific bioconjugation methods, more potent payloads, environment-specific cleavable linkers, more efficient protein-based targeting systems and new analytical tools for acute characterization. This will be achieved by exposing the ESRs to the leading intersectoral research scientists and laboratories in Europe who are active in this field. In doing so, TACT combines state-of-the-art research with excellent training in PDCs, one of the hot topics in cancer and targeted therapies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TACT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TACT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

DESIGN-EID (2020)

Defect Simulation and Material Growth of III-V Nanostructures- European Industrial Doctorate Program

Read More  

TACT (2020)

Targeted Anti-Cancer Therapies

Read More  

INSPIRE (2019)

INNOVATIVE GROUND INTERFACE CONCEPTS FOR STRUCTURE PROTECTION

Read More